ONE-STOP-SITE
LIVE

Serial Number

79295569

Owner

Hovione Scientia Limited

Attorney

R. Peter Spies

Filing Date

Jun 2, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ONE-STOP-SITE Trademark

Serial Number: 79295569 • Registration: 6458312

ONE-STOP-SITE is a trademark filed by Hovione Scientia Limited on June 2, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Hovione Scientia Limited (16 trademarks)

Loughbeg

Entity Type: 99

Trademark Details

Filing Date

June 2, 2020

Registration Date

August 24, 2021

Published for Opposition

June 8, 2021

Goods & Services

Active chemical ingredients for use in the manufacture of pharmaceuticals for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals

Compositions for medical and veterinarian use, namely, chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; pharmaceutical active ingredients, namely, sold as a component ingredient of pharmaceutical preparations, and pharmaceutical preparations and compounds, all of the foregoing for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals

Development of pharmaceutical products and drug products; research on pharmaceutical products and drug products; research and development of new products in the pharmaceutical industry; Consulting services in the field of design and development of engineering processes for the pharmaceutical industry; research and development services in the pharmaceutical field; research and development services in the field of pharmaceuticals, chemical preparations, vaccines, medicines, antibodies, new products in the medical field

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 7, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
May 26, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 28, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 4, 2022 FICS
FINAL DISPOSITION PROCESSED
Feb 3, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 24, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 24, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 8, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 8, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 19, 2021 NONP
NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2021 NREP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 5, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 4, 2021 TROA
REFUSAL PROCESSED BY IB
Nov 29, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 6, 2020 RFCS
REFUSAL PROCESSED BY MPU
Nov 5, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Oct 20, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 16, 2020 RFCR
NON-FINAL ACTION WRITTEN
Oct 15, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 14, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 14, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 8, 2020 REPR